98 related articles for article (PubMed ID: 6288238)
1. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
Schwade JG; Makuch RW; Strong JM; Glatstein E
Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
[TBL] [Abstract][Full Text] [Related]
2. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
Walker MD; Strike TA
Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of misonidazole and peripheral neuropathy.
Marten TR
Am J Clin Oncol; 1982 Apr; 5(2):239-40. PubMed ID: 6283876
[No Abstract] [Full Text] [Related]
4. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
5. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
Saunders ME; Dische S; Anderson P; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
Workman P
Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
[TBL] [Abstract][Full Text] [Related]
7. The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.
Wasserman TH; Phillips TL; Van Raalte G; Urtasun R; Partington J; Koziol D; Schwade JG; Gangji D; Strong JM
Br J Radiol; 1980 Feb; 53(626):172-3. PubMed ID: 6245744
[No Abstract] [Full Text] [Related]
8. Peripheral neuropathy related to misonidazole: incidence and pathology.
Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
[TBL] [Abstract][Full Text] [Related]
9. Misonidazole neuropathy.
Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
[TBL] [Abstract][Full Text] [Related]
10. The neurotoxicity of misonidazole: pooling of data from five centres.
Disch S; Saunders MI; Anderson P; Urtasun RC; Karcher KH; Kogelnik HD; Bleehen N; Phillips TL; Wasserman TH
Br J Radiol; 1978 Dec; 51(612):1023-4. PubMed ID: 216455
[No Abstract] [Full Text] [Related]
11. Clinical experience with misonidazole: high dose fractions versus daily low doses.
Kogelnik HD
Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
13. Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract.
Strong JM; Schwade JG; Gangji D; Shoemaker DD; Upton DK
Cancer Clin Trials; 1981; 4(1):41-6. PubMed ID: 7214661
[No Abstract] [Full Text] [Related]
14. Misonidazole in the clinic at Mount Vernon.
Dische S
Cancer Clin Trials; 1980; 3(2):175-8. PubMed ID: 7000388
[TBL] [Abstract][Full Text] [Related]
15. Misonidazole Neuropathy: a clinical, electrophysiological, and histological study.
Melgaard B; Hansen HS; Kamieniecka Z; Paulson OB; Pedersen AG; Tang X; Trojaborg W
Ann Neurol; 1982 Jul; 12(1):10-7. PubMed ID: 7114817
[TBL] [Abstract][Full Text] [Related]
16. Misonidazole in patients receiving radical radiotherapy: pharmacokinetic effects of phenytoin, tumor response and neurotoxicity.
Moore JL; Paterson IC; Dawes PJ; Henk JM
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):361-4. PubMed ID: 7107352
[TBL] [Abstract][Full Text] [Related]
17. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
18. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Dische S; Saunders MI; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
Asakawa H; Watarai J; Hoshino T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
